Skip to main content

Table 6 Cox multivariate regression model. (A) metastatic gastric cancer patients. (B) Non-metastatic gastric cancer patients

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

Variables in the equation
  B df Sig. Exp(B) 95.0% CI
Lower Upper
(A) Cox multivariate regression model for metastatic gastric cancer
BCc1 nanomedicine indicator − 0.743 1 0.039 0.476 0.235 0.962
Chemotherapy indicator − 0.306 1 0.388 0.737 0.368 1.474
(B) Cox multivariate regression model for non-metastatic gastric cancer
BCc1 nanomedicine indicator − 1.316 1 0.057 0.268 0.069 1.042
Chemotherapy-indicator 0.401 1 0.535 1.494 0.420 5.315